Patent Application: Cancer Treatment Methods and Compositions

ChangeBridge: Patent Apps - Pharma (A61K)

Published September 19th, 2025

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260083752A1) for methods and compositions for treating cancer. The application, filed by the Regents of the University of Minnesota, involves the combination of p300/CBP modulators with senotherapeutics.

View original document View source feed page

What changed

This document is a published patent application from the USPTO detailing novel methods and compositions for cancer treatment. The application, filed by the Regents of the University of Minnesota, specifically covers the administration of a p300/CBP modulator in combination with a senotherapeutic agent. The abstract outlines the core invention, which aims to provide new therapeutic strategies for cancer patients.

As this is a patent application, it does not impose direct regulatory obligations on pharmaceutical companies or healthcare providers. However, it represents a potential future development in cancer therapeutics. Companies involved in oncology drug development may wish to review this application for insights into emerging research areas and potential intellectual property landscapes. No compliance actions or deadlines are associated with this publication.

Source document (simplified)

← USPTO Patent Applications

PHARMACEUTICAL METHODS, COMPOSITIONS AND COMBINATIONS

Application US20260083752A1 Kind: A1 Mar 26, 2026

Assignee

Regents of the University of Minnesota

Inventors

Darko Bosnakovski, Erdong Wei

Abstract

Disclosed herein are methods for treating cancer in an animal in need thereof, comprising administering to the animal a p300/CBP (p300 and/or CBP) modulator or a pharmaceutically acceptable salt thereof and a senotherapeutic (e.g., a senolytic or senomorphic) or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions and pharmaceutical combinations, comprising a p300/CBP (p300 and/or CBP) modulator or a pharmaceutically acceptable salt thereof and a senotherapeutic (e.g., a senolytic or senomorphic) or a pharmaceutically acceptable salt thereof.

CPC Classifications

A61K 31/553 A61K 31/352 A61K 31/404 A61K 31/4184 A61K 31/423 A61K 31/4412 A61K 31/4439 A61K 31/444 A61K 31/454 A61K 31/47 A61K 31/4745 A61K 31/496 A61K 31/501 A61K 31/5025 A61K 31/506 A61K 31/519 A61K 31/5377 A61K 31/635 A61K 47/545 A61K 47/55 A61P 35/00